A comparative study of single-target (CD19) versus dual-target (tandem or sequential CD19/CD22) CAR-T therapy in R/R B-ALL found no difference in efficacy between the tandem and sequential CD19/CD22 therapies; however, both were superior to the single-target CAR-T therapy [24]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.